Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Perfusion Imaging | 7 | 2020 | 10 | 3.440 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 21 | 2.830 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 7 | 2020 | 19 | 2.490 |
Why?
|
| Myocardial Ischemia | 4 | 2020 | 9 | 1.870 |
Why?
|
| Purines | 4 | 2016 | 10 | 1.470 |
Why?
|
| Pyrazoles | 4 | 2016 | 14 | 1.460 |
Why?
|
| Myocardial Infarction | 3 | 2020 | 21 | 1.240 |
Why?
|
| Kidney Failure, Chronic | 2 | 2021 | 26 | 1.110 |
Why?
|
| Aminophylline | 2 | 2016 | 3 | 0.890 |
Why?
|
| Heart Failure | 2 | 2020 | 29 | 0.770 |
Why?
|
| Humans | 15 | 2022 | 5837 | 0.770 |
Why?
|
| Middle Aged | 9 | 2022 | 1775 | 0.720 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 22 | 0.660 |
Why?
|
| Insurance Coverage | 1 | 2020 | 2 | 0.630 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 11 | 0.630 |
Why?
|
| Defibrillators, Implantable | 1 | 2020 | 4 | 0.630 |
Why?
|
| Medicaid | 1 | 2020 | 15 | 0.620 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 31 | 0.620 |
Why?
|
| Male | 10 | 2022 | 3399 | 0.620 |
Why?
|
| Nuclear Medicine | 1 | 2019 | 1 | 0.620 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 1 | 0.620 |
Why?
|
| Female | 10 | 2022 | 3346 | 0.610 |
Why?
|
| Exercise Test | 5 | 2020 | 22 | 0.610 |
Why?
|
| Medicare | 1 | 2019 | 30 | 0.610 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 24 | 0.600 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 23 | 0.580 |
Why?
|
| Heart | 2 | 2021 | 24 | 0.550 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2015 | 2 | 0.470 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 4 | 0.470 |
Why?
|
| Technetium | 1 | 2015 | 2 | 0.450 |
Why?
|
| Aged | 6 | 2022 | 1860 | 0.450 |
Why?
|
| Stroke Volume | 3 | 2020 | 6 | 0.430 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 163 | 0.420 |
Why?
|
| Hyperemia | 1 | 2014 | 2 | 0.410 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 6 | 0.410 |
Why?
|
| Thrombosis | 1 | 2014 | 16 | 0.410 |
Why?
|
| Perfusion | 3 | 2020 | 10 | 0.390 |
Why?
|
| Primary Health Care | 1 | 2013 | 16 | 0.380 |
Why?
|
| Prognosis | 3 | 2020 | 138 | 0.360 |
Why?
|
| Retrospective Studies | 4 | 2022 | 584 | 0.350 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 125 | 0.310 |
Why?
|
| Atrial Appendage | 2 | 2022 | 4 | 0.290 |
Why?
|
| Risk Assessment | 2 | 2021 | 112 | 0.270 |
Why?
|
| Coronary Angiography | 2 | 2020 | 16 | 0.270 |
Why?
|
| United States | 2 | 2020 | 502 | 0.270 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 6 | 0.220 |
Why?
|
| Double-Blind Method | 2 | 2016 | 78 | 0.220 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 333 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2016 | 411 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2015 | 406 | 0.190 |
Why?
|
| Pulmonary Veins | 1 | 2022 | 2 | 0.190 |
Why?
|
| Sex Characteristics | 1 | 2021 | 36 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 48 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 6 | 0.160 |
Why?
|
| Ischemia | 1 | 2020 | 7 | 0.160 |
Why?
|
| Utilization Review | 1 | 2020 | 1 | 0.160 |
Why?
|
| Electric Countershock | 1 | 2020 | 4 | 0.160 |
Why?
|
| Registries | 1 | 2020 | 45 | 0.160 |
Why?
|
| Comorbidity | 2 | 2021 | 98 | 0.150 |
Why?
|
| Prospective Payment System | 1 | 2019 | 1 | 0.150 |
Why?
|
| Outpatients | 1 | 2019 | 11 | 0.150 |
Why?
|
| Hospitals | 1 | 2019 | 31 | 0.150 |
Why?
|
| Organophosphorus Compounds | 1 | 2016 | 4 | 0.120 |
Why?
|
| Organotechnetium Compounds | 1 | 2016 | 6 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 7 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 36 | 0.120 |
Why?
|
| Age Distribution | 1 | 2015 | 12 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 21 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2015 | 16 | 0.120 |
Why?
|
| Survival Rate | 1 | 2015 | 60 | 0.110 |
Why?
|
| Adult | 1 | 2020 | 1670 | 0.110 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 4 | 0.110 |
Why?
|
| Rest | 1 | 2015 | 15 | 0.110 |
Why?
|
| Incidence | 1 | 2015 | 165 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 40 | 0.110 |
Why?
|
| ROC Curve | 1 | 2015 | 34 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 19 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 53 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 46 | 0.110 |
Why?
|
| Prevalence | 1 | 2015 | 72 | 0.110 |
Why?
|
| Chicago | 1 | 2015 | 239 | 0.110 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2014 | 1 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 2 | 0.100 |
Why?
|
| Placebo Effect | 1 | 2014 | 2 | 0.100 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 7 | 0.100 |
Why?
|
| Image Enhancement | 1 | 2014 | 8 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2013 | 6 | 0.100 |
Why?
|
| Cause of Death | 1 | 2013 | 15 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 1034 | 0.080 |
Why?
|
| Lasers | 1 | 2022 | 5 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 52 | 0.050 |
Why?
|
| Illinois | 1 | 2021 | 52 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 30 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 55 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 86 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 65 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2022 | 601 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 203 | 0.040 |
Why?
|